Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Third Affiliated Hospital of Harbin Medical University, Fudan University, Fudan University Shanghai Cancer Center, First Hospital of Jilin University, First Bethune Hospital of Jilin University, Tianjin Medical University Cancer Institute and Hospital, Liaoning Cancer Hospital & Institute, First Hospital of China Medical University, Hubei Cancer Hospital, Hunan Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Wuhan Union Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Jiangsu Cancer Hospital, Zhejiang Cancer Hospital, Jiangsu Hengrui Medicine (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3189200395